ENTRY       D06622                      Drug
NAME        Nebivolol hydrochloride (USAN);
            Bystolic (TN)
PRODUCT     BYSTOLIC (A-S Medication Solutions)
            BYSTOLIC (A-S Medication Solutions)
            BYSTOLIC (Allergan)
  GENERIC   NEBIVOLOL (A-S Medication Solutions)
            NEBIVOLOL (A-S Medication Solutions)
            NEBIVOLOL (A-S Medication Solutions)
            NEBIVOLOL (A-S Medication Solutions)
            NEBIVOLOL (ANI Pharmaceuticals)
            NEBIVOLOL (Ajanta Pharma USA)
            NEBIVOLOL (American Health Packaging)
            NEBIVOLOL (Ascend Laboratories)
            NEBIVOLOL (Aurobindo Pharma Limited)
            NEBIVOLOL (Bryant Ranch Prepack)
            NEBIVOLOL (Bryant Ranch Prepack)
            NEBIVOLOL (Bryant Ranch Prepack)
            NEBIVOLOL (Cadila Pharmaceuticals Limited)
            NEBIVOLOL (Camber Pharmaceuticals)
            NEBIVOLOL (Glenmark Pharmaceuticals)
            NEBIVOLOL (Golden State Medical Supply)
            NEBIVOLOL (Lifestar Pharma LLC)
            NEBIVOLOL (Major Pharmaceuticals)
            NEBIVOLOL (Modavar Pharmaceuticals LLC)
            NEBIVOLOL (REMEDYREPACK)
            NEBIVOLOL (Solco Healthcare US)
            NEBIVOLOL (Torrent Pharmaceuticals Limited)
            NEBIVOLOL HYDROCHLORIDE (Unichem Pharmaceuticals (USA))
FORMULA     C22H25F2NO4. HCl
EXACT_MASS  441.1518
MOL_WEIGHT  441.8959
CLASS       Cardiovascular agent
             DG01466  Adrenergic receptor antagonist
              DG01464  beta-Adrenergic receptor antagonist (Beta blocker)
               DG01461  beta1-Adrenergic receptor antagonist
             DG03231  Antihypertensive
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
REMARK      ATC code: C07AB12
            Chemical structure group: DG00319
            Product (DG00319): D06622<US>
EFFICACY    Antihypertensive, Vasodilator, beta1-Adrenergic receptor antagonist
  DISEASE   Hypertension [DS:H01633]
COMMENT     Highly selective b1 antagonist with non-adrenergic vasodilating properties due to the release of nitric oxide from vascular endothelium, studied in the treatment of hypertension, congestive heart failure and other cardiovascular events
TARGET      ADRB1 [HSA:153] [KO:K04141]
  PATHWAY   hsa04080(153)  Neuroactive ligand-receptor interaction
            hsa04261(153)  Adrenergic signaling in cardiomyocytes
METABOLISM  Enzyme: CYP2D6 [HSA:1565]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C07 BETA BLOCKING AGENTS
               C07A BETA BLOCKING AGENTS
                C07AB Beta blocking agents, selective
                 C07AB12 Nebivolol
                  D06622  Nebivolol hydrochloride (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Cardiovascular Agents
              Beta-adrenergic Blocking Agents
               Beta-1 Selective
                Nebivolol
                 D06622  Nebivolol hydrochloride (USAN)
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01466  Adrenergic receptor antagonist
               DG01464  beta-Adrenergic receptor antagonist (Beta blocker)
                DG01461  beta1-Adrenergic receptor antagonist
                 DG00319  Nebivolol
                  D06622  Nebivolol hydrochloride
              DG03231  Antihypertensive
               DG00319  Nebivolol
                D06622  Nebivolol hydrochloride
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00319  Nebivolol
                D06622  Nebivolol hydrochloride
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG03231  Antihypertensive
               D06622  Nebivolol hydrochloride
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Adrenaline
                ADRB1
                 D06622  Nebivolol hydrochloride (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D06622
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D06622
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D06622
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01466  Adrenergic receptor antagonist
               DG01464  beta-Adrenergic receptor antagonist (Beta blocker)
                DG01461  beta1-Adrenergic receptor antagonist
                 DG00319  Nebivolol
              DG03231  Antihypertensive
               DG00319  Nebivolol
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00319  Nebivolol
DBLINKS     CAS: 152520-56-4
            PubChem: 47208273
            ChEBI: 132912
            LigandBox: D06622
ATOM        30
            1   C8x C     9.1244  -16.2075
            2   C8y C     9.1244  -17.6104
            3   C8x C    10.3392  -18.3119
            4   C8y C    11.5543  -17.6104
            5   C8y C    11.5543  -16.2075
            6   C8x C    10.3392  -15.5060
            7   C1x C    12.7692  -18.3119
            8   C1x C    13.9842  -17.6104
            9   C1y C    13.9842  -16.2075
            10  O2x O    12.7692  -15.5060
            11  C1c C    15.1843  -15.5145
            12  X   F     7.9094  -18.3119
            13  C1b C    16.3751  -16.2019
            14  O1a O    15.1844  -14.1033
            15  N1b N    17.5684  -15.5129
            16  C1b C    18.7605  -16.2011
            17  C1c C    19.9531  -15.5125
            18  C1y C    21.1457  -16.2009
            19  O1a O    19.9532  -14.1032
            20  C1x C    21.1458  -17.6102
            21  C1x C    22.3609  -18.3115
            22  C8y C    23.5758  -17.6099
            23  C8y C    23.5756  -16.2007
            24  O2x O    22.3606  -15.4994
            25  C8x C    24.7908  -18.3113
            26  C8y C    26.0057  -17.6097
            27  C8x C    26.0056  -16.2005
            28  C8x C    24.7906  -15.4992
            29  X   F    27.2390  -18.3218
            30  X   Cl   29.3300  -16.0300
BOND        32
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11    5  10 1
            12    9  11 1
            13    2  12 1
            14   11  13 1
            15   11  14 1 #Up
            16   13  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 1
            20   17  19 1 #Down
            21   18  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   23  24 1
            26   18  24 1
            27   22  25 2
            28   25  26 1
            29   26  27 2
            30   27  28 1
            31   23  28 2
            32   26  29 1
///
